Tenofovir diphosphate (TFV-DP) in dried blood spots (DBS) is a marker of cumulative tenofovir disoproxil fumarate (TDF) exposure and a predictor of PrEP efficacy. However, the predictive value of TFV-DP in HIV infection has not been evaluated.
DBS for TFV-DP were prospectively obtained from a clinical cohort of HIV-infected individuals on TDF-based therapy (any duration of time) using convenience sampling at the time of their clinic visits, for up to 3 visits over 48-weeks. Log-transformed baseline TFV-DP comparisons utilized t-tests or ANOVA, and are presented as geometric mean [95% CI] fmol/punch. Generalized estimating equations with a logit link, which accounted for repeated measures, were used to estimate the adjusted odds ratio (aOR) of viral suppression (<20 copies/mL) based on the TFV-DP concentration at the time of the study visit. TFV-DP was categorized by the expected number of doses/wk according to a previously completed directly-observed dosing study in HIV negative adults.
A total of 1,198 person-visits from 532 participants (76 female, 79 Black, 106 Hispanic) were analyzed. Among the virologically-suppressed participants at baseline (n=347), TFV-DP was lower in Blacks (1428 [1251,1630]) vs. Whites (1793 [1678,1916], P=0.002), and vs. Hispanics (1752 [1557,1972], P=0.02); in non-boosted (1614 [1508,1727]) vs. boosted (1884 [1745,2033], P=0.003) regimens, and; in NNRTI-based (1563 [1432,1707]) vs. PI-based (1890 [1704,2095], P=0.006), and vs. multiclass-based (1927 [1650,2252], P=0.02) regimens. The aOR of virologic suppression, after adjusting for age, gender, race, body mas index, serum creatinine, CD4+ T cell count, antiretroviral drug class, duration of therapy and dosing category was 76.5 (95% CI; 26.6-220.5) for a TFV-DP concentration ≥1850 fmol/punch (75th percentile of daily dosing) compared to <350 fmol/punch (<2 doses/wk), as shown in the Figure. The median HIV viral load decreased with higher TFV-DP concentrations; most HIV viral loads were <200 copies/mL in the highest TFV-DP categories.
TFV-DP in DBS is a powerful predictor of virologic suppression in HIV-infected individuals on TDF-based therapy, after controlling for clinically-relevant covariates, and a promising adherence tool in this population. TFV-DP showed slight differences across subgroups. Additional research is required to assess the contributions of antiretroviral adherence versus biology/pharmacology on TFV-DP concentrations among these subgroups.